{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:26:22Z","timestamp":1768479982131,"version":"3.49.0"},"reference-count":38,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"CME\/CNE Information<\/jats:title>\n Activity Available Online:<\/jats:p>\n To access the article, post-test, and evaluation online, go to http:\/\/www.cmscscholar.org.<\/jats:p>\n Target Audience:<\/jats:p>\n The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS).<\/jats:p>\n Learning Objectives: Apply new information about MS to a comprehensive individualized treatment plan for patients with MS Integrate the team approach into long-term planning in order to optimize rehabilitation care of patients with MS<\/jats:p>\n Accreditation Statement:<\/jats:p>\n This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and Delaware Media Group. The CMSC is accredited by the ACCME to provide continuing medical education for physicians.<\/jats:p>\n The CMSC designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)\u2122. Physicians should claim only the credit commensurate with the extent of their participation in the activity.<\/jats:p>\n Nurse Practitioner Alternatives (NPA) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.<\/jats:p>\n NPA designates this enduring material for 1.0 Continuing Nursing Education credit.<\/jats:p>\n Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has disclosed no relevant financial relationships.<\/jats:p>\n Disclosures:<\/jats:p>\n Francois Bethoux, MD, Editor in Chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has received royalties from Springer Publishing and has received intellectual property rights from Biogen.<\/jats:p>\n Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has disclosed no relevant financial relationships.<\/jats:p>\n Scott D. Newsome, DO, MSCS (author), has served on scientific advisory boards for Biogen, Genentech, Novartis, and Genzyme, and has performed contracted research (institution received funds) for Biogen, Genentech, and Novartis.<\/jats:p>\n Philip J. Aliotta, MD, MSHA, CHCQM, FACS (author), has served on speakers' bureaus for Astellas Pharma, Actavis, Augmenix, and Allergan and has performed contracted research for Allergan.<\/jats:p>\n Jacquelyn Bainbridge, PharmD (author), has disclosed no relevant financial relationships.<\/jats:p>\n Susan E. Bennett, PT, DPT, EdD, NCS, MSCS (author), has served on speakers' bureaus for Acorda Therapeutics, Biogen, and Medtronic; has received consulting fees from and performed contracted research for Acorda Therapeutics; and is chair of the Clinical Events Committee at Innovative Technologies.<\/jats:p>\n Gary Cutter, PhD (author), has participated on Data and Safety Monitoring Committees for AMO Pharma, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech\/Prolor, Merck, Merck\/Pfizer, Opko Biologics, Neuren, Sanofi-Aventis, Reata Pharmaceuticals, Receptos\/Celgene, Teva Pharmaceuticals, NHLBI (Protocol Review Committee), and NICHD (OPRU Oversight Committee); has received consulting fees from and\/or served on speakers' bureaus and scientific advisory boards for Cerespir, Genzyme, Genentech, Innate Therapeutics, Janssen Pharmaceuticals, Klein-Buendel Incorporated, MedImmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara, Somahlution, Teva Pharmaceuticals, Transparency Life Sciences, and TG Therapeutics; and is President of Pythagoras, Inc., a private consulting company located in Birmingham, AL.<\/jats:p>\n Kaylan Fenton, CRNP, APNP, MSCN (author), has disclosed no relevant financial relationships.<\/jats:p>\n Fred Lublin, MD (author), has received consulting fees\/fees for non-CME\/CE activities from Bayer HealthCare Pharmaceuticals, Biogen, EMD Serono, Novartis, Teva Neuroscience, Actelion, Sanofi\/Genzyme, Acorda, Questcor\/Mallinckrodt, Roche\/Genentech, MedImmune, Osmotica, Xenoport, Receptos\/Celgene, Forward Pharma, Akros, TG Therapeutics, AbbVie, Toyama, Amgen, Medday, Atara Biotherapeutics, Polypharma, Pfizer, Johnson & Johnson, Revalesio, Coronado Bioscience, and Bristol-Myers Squibb; has served on speakers' bureaus for Genentech\/Roche and Genzyme\/Sanofi; has performed contracted research for Acorda, Biogen, Novartis, Teva Neuroscience, Genzyme, Xenoport, and Receptos; is the co\u2013chief editor of Multiple Sclerosis and Related Disorders; and has an ownership interest in Cognition Pharmaceuticals.<\/jats:p>\n Dorothy Northrop, MSW, ACSW (author), has disclosed no relevant financial relationships.<\/jats:p>\n David Rintell, EdD (author), has received consulting fees from Novartis and has served as a patient education speaker for Teva Neuroscience. He started as a salaried employee of Sanofi Genzyme in November 2015. Dr. Rintell's work on this project was completed before he became a salaried employee of Sanofi Genzyme.<\/jats:p>\n Bryan D. Walker, MHS, PA-C (author), has served on scientific advisory boards for EMD Serono and Sanofi Genzyme and owns stock in Biogen.<\/jats:p>\n Megan Weigel, DNP, ARNP-C, MSCN (author), has received consulting fees from Mallinckrodt, Genzyme, and Genentech, and has served on speakers' bureaus for Bayer Corp, Acorda Therapeutics, Teva Neuroscience, Biogen, Mallinckrodt, Genzyme, Novartis, and Pfizer.<\/jats:p>\n Kathleen Zackowski, PhD, OTR, MSCS (author), has performed contracted research for Acorda Therapeutics.<\/jats:p>\n David E. Jones, MD (author), has received consulting fees from Biogen and Novartis, and has performed contracted research for Biogen.<\/jats:p>\n One anonymous peer reviewer for the IJMSC has performed contracted research (institution received funds) for Novartis, Chugai, and Biogen. Another reviewer has received consulting fees and served on speakers' bureaus for Biogen, Sanofi Genzyme, Genentech, EMD Serono, and Novartis. The third reviewer has disclosed no relevant financial relationships.<\/jats:p>\n Lori Saslow, MS (medical writer), has disclosed no relevant financial relationships.<\/jats:p>\n The staff at the IJMSC, CMSC, NPA, and Delaware Media Group who are in a position to influence content have disclosed no relevant financial relationships.<\/jats:p>\n Note: Disclosures listed for authors are those applicable at the time of their work on this project and within 12 months previously. Financial relationships for some authors may have changed in the interval between the time of their work on this project and publication of the article.<\/jats:p>\n Funding\/Support:<\/jats:p>\n Funding for the Framework of Care consensus conference was provided by the Consortium of Multiple Sclerosis Centers, Mallinckrodt Pharmaceuticals, and Mylan Pharmaceuticals.<\/jats:p>\n Method of Participation:<\/jats:p>\n Release Date: December 1, 2016<\/jats:p>\n Valid for Credit Through: December 1, 2017<\/jats:p>\n In order to receive CME\/CNE credit, participants must:Review the CME\/CNE information, including learning objectives and author disclosures.Study the educational content.Complete the post-test and evaluation, which are available at http:\/\/www.cmscscholar.org.<\/jats:p>\n Statements of Credit are awarded upon successful completion of the post-test with a passing score of &gt;70% and the evaluation.<\/jats:p>\n There is no fee to participate in this activity.<\/jats:p>\n Disclosure of Unlabeled Use:<\/jats:p>\n This CME\/CNE activity may contain discussion of published and\/or investigational uses of agents that are not approved by the FDA. CMSC, NPA, and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC, NPA, or Delaware Media Group.<\/jats:p>\n Disclaimer:<\/jats:p>\n Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health-care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.<\/jats:p>","DOI":"10.7224\/1537-2073.2016-051","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T12:33:34Z","timestamp":1481891614000},"page":"314-323","source":"Crossref","is-referenced-by-count":10,"title":["A Framework of Care in Multiple Sclerosis, Part 1"],"prefix":"10.7224","volume":"18","author":[{"given":"Scott D.","family":"Newsome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Aliotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn","family":"Bainbridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Cutter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylan","family":"Fenton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Lublin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"Northrop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rintell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan D.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Weigel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Zackowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","reference":[{"key":"2020060301013776800_i1537-2073-18-6-314-b1","unstructured":"Halper\n J\n , HarrisC.\n Nursing Practice in Multiple Sclerosis: A Core Curriculum. 3rd ed. New York, NY: Springer Publishing Co; 2012."},{"key":"2020060301013776800_i1537-2073-18-6-314-b2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/135245859800400504","article-title":"A comprehensive assessment of the cost of multiple sclerosis in the United States","volume":"4","author":"Whetten-Goldstein","year":"1998","journal-title":"Mult Scler"},{"key":"2020060301013776800_i1537-2073-18-6-314-b3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/NRE-1994-4203","article-title":"Care patterns in multiple sclerosis: principal care, comprehensive team care, consortium care","volume":"4","author":"Halper","year":"1994","journal-title":"NeuroRehabilitation"},{"key":"2020060301013776800_i1537-2073-18-6-314-b4","article-title":"The use of disease-modifying therapies in multiple sclerosis: principles and current evidence","author":"Costello"},{"key":"2020060301013776800_i1537-2073-18-6-314-b5","article-title":"Medications","author":"Emerging Therapies Collaborative"},{"key":"2020060301013776800_i1537-2073-18-6-314-b6","article-title":"Medications","author":"National Multiple Sclerosis Society"},{"key":"2020060301013776800_i1537-2073-18-6-314-b7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1212\/WNL.0000000000001965","article-title":"Quality improvement in neurology: multiple sclerosis quality measures: executive summary","volume":"85","author":"Rae-Grant","year":"2015","journal-title":"Neurology"},{"key":"2020060301013776800_i1537-2073-18-6-314-b8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"2020060301013776800_i1537-2073-18-6-314-b9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"2020060301013776800_i1537-2073-18-6-314-b10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"2020060301013776800_i1537-2073-18-6-314-b11","first-page":"94","article-title":"Relapse management in multiple sclerosis","author":"Fox","year":"2013","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"2020060301013776800_i1537-2073-18-6-314-b12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.02.008","article-title":"Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later","volume":"292","author":"Scott","year":"2010","journal-title":"J Neurol Sci"},{"key":"2020060301013776800_i1537-2073-18-6-314-b13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1212\/WNL.55.5.689","article-title":"Short-term prognosis in early relapsing-remitting multiple sclerosis","volume":"55","author":"Scott","year":"2000","journal-title":"Neurology"},{"issue":"pt 3","key":"2020060301013776800_i1537-2073-18-6-314-b14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/brain\/121.3.495","article-title":"The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up","volume":"121","author":"O'Riordan","year":"1998","journal-title":"Brain J Neurol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b15","doi-asserted-by":"crossref","first-page":"e90509","DOI":"10.1371\/journal.pone.0090509","article-title":"Radiologically isolated syndrome: 5-year risk for an initial clinical event","volume":"9","author":"Okuda","year":"2014","journal-title":"PLoS One"},{"key":"2020060301013776800_i1537-2073-18-6-314-b16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Treatment optimization in MS: Canadian MS Working Group updated recommendations","volume":"40","author":"Freedman","year":"2013","journal-title":"Can J Neurol Sci"},{"key":"2020060301013776800_i1537-2073-18-6-314-b17","article-title":"Position statement: availability of disease modifying therapies (DMT) for treatment of relapsing forms of multiple sclerosis","author":"American Academy of Neurology"},{"key":"2020060301013776800_i1537-2073-18-6-314-b18","article-title":"Factors that determine disease course: early changes contribute to predict long-term prognosis: the \u201cBarcelona inception cohort.\u201d","author":"Tintore"},{"issue":"suppl 6","key":"2020060301013776800_i1537-2073-18-6-314-b19","first-page":"18","article-title":"Therapeutic approach for patients with aggressive onset or poor prognostic indicators in MS","volume":"16","author":"Ford","year":"2014","journal-title":"Int J MS Care"},{"key":"2020060301013776800_i1537-2073-18-6-314-b20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis","volume":"37","author":"Traboulsee","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b22","article-title":"Addressing concerns regarding the use of gadolinium in a standardized MRI protocol for the diagnosis and follow-up of multiple sclerosis [published online ahead of print September 1, 2016]","author":"Traboulsee","journal-title":"AJNR Am J Neuroradiol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u201cno evidence of disease activity\u201d in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"2020060301013776800_i1537-2073-18-6-314-b24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"2020060301013776800_i1537-2073-18-6-314-b26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"2020060301013776800_i1537-2073-18-6-314-b27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"2020060301013776800_i1537-2073-18-6-314-b28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b29","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"2020060301013776800_i1537-2073-18-6-314-b30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1468-1331.2009.02708.x","article-title":"One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis","volume":"16","author":"Prosperini","year":"2009","journal-title":"Eur J Neurol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/1352458515599246","article-title":"Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis","volume":"22","author":"Zecca","year":"2016","journal-title":"Mult Scler"},{"key":"2020060301013776800_i1537-2073-18-6-314-b32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamaneurol.2014.4147","article-title":"Comparison of switch to fingolimod or interferon beta\/glatiramer acetate in active multiple sclerosis","volume":"72","author":"He","year":"2015","journal-title":"JAMA Neurol"},{"key":"2020060301013776800_i1537-2073-18-6-314-b33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.24339","article-title":"Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis","volume":"77","author":"Kalincik","year":"2015","journal-title":"Ann Neurol"},{"issue":"suppl","key":"2020060301013776800_i1537-2073-18-6-314-b34","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1177\/1352458509347131","article-title":"Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy","volume":"15","author":"Coyle","year":"2009","journal-title":"Mult Scler"},{"key":"2020060301013776800_i1537-2073-18-6-314-b35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40263-013-0042-5","article-title":"Switching therapies in multiple sclerosis","volume":"27","author":"Coyle","year":"2013","journal-title":"CNS Drugs"},{"key":"2020060301013776800_i1537-2073-18-6-314-b36","article-title":"Consensus opinion of US neurologists on practice patterns in radiologically and clinically isolated syndrome and relapsing-remitting MS","author":"Tornatore"},{"key":"2020060301013776800_i1537-2073-18-6-314-b37","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-008-0911-x","article-title":"Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS","volume":"255","author":"Arnold","year":"2008","journal-title":"J Neurol"},{"issue":"suppl 2","key":"2020060301013776800_i1537-2073-18-6-314-b38","first-page":"17","article-title":"The manifold economic impact of multiple sclerosis: indirect and direct costs of managing patients","volume":"7","author":"Brandes","year":"2012","journal-title":"Eur Neurol Rev"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/6\/314\/2092415\/1537-2073_2016-051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/6\/314\/2092415\/1537-2073_2016-051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:44Z","timestamp":1752786764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/a-framework-of-care-in-multiple-sclerosis-part-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2016-051","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,1]]}}}